Gsk annual ebitda
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Gsk EBITDA Growth & History (GSK)
Gsk's calculated EBITDA was £10.25B for fiscal 2025.
View full Gsk company overviewGsk annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £10.25B | £3.67B | +55.90% |
| 2024 | 2024-12-31 | £6.57B | −£2.47B | −27.29% |
| 2023 | 2023-12-31 | £9.04B | £459.0M | +5.35% |
| 2022 | 2022-12-31 | £8.58B | £2.10B | +32.43% |
| 2021 | 2021-12-31 | £6.48B | −£1.55B | −19.31% |
| 2020 | 2020-12-31 | £8.03B | −£1.27B | −13.62% |
| 2019 | 2019-12-31 | £9.29B | £1.96B | +26.65% |
| 2018 | 2018-12-31 | £7.34B | £1.33B | +22.13% |
| 2017 | 2017-12-31 | £6.01B | £1.64B | +37.44% |
| 2016 | 2016-12-31 | £4.37B | −£7.58B | −63.42% |
| 2015 | 2015-12-31 | £11.95B | — | — |
Gsk quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | £2.83B | −£404.0M | −12.51% |
| Q1 2026 | 2026-03-31 | £2.77B | — | — |
| Q4 2025 | 2025-12-31 | £1.12B | — | — |
| Q3 2025 | 2025-09-30 | £3.36B | — | — |
| Q2 2025 | 2025-06-30 | £3.23B | — | — |
Gsk ebitda trends
Over the last five fiscal years, Gsk's ebitda increased from £8.03B to £10.25B, a change of £2.22B. The latest reported quarter, Q2 2026, shows £2.83B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gsk source filings ↗Community posts
GSK presents Jideytro data supporting a potential first-line lung-cancer filing
GSK ($GSK) reported a 94% response rate for Jideytro in 94 evaluable patients with ROS1-positive advanced lung cancer who had not previously received a ROS1 tyrosine kinase inhibitor. In the single-arm Phase 1/2 ARROS-1 study, 90% were prog ...
